首页 > 最新文献

Reumatologia Clinica最新文献

英文 中文
Fabry disease in familial Mediterranean fever according to the severity of the disease 法布里病在家族性地中海热中的严重程度
IF 1.2 Q4 RHEUMATOLOGY Pub Date : 2024-11-01 DOI: 10.1016/j.reuma.2024.09.002
Sadettin Uslu , Gökhan Kabadayi , Pelin Teke Kısa , Tuba Yüce Inel , Zümrüt Arslan , Nur Arslan , Servet Akar , Fatos Onen , Ismail Sari

Objectives

Mutations in the α-galactosidase A (GLA) gene result in Fabry disease (FD), a rare metabolic condition. FD patients present with heterogeneous clinical manifestations, which may overlap with systemic diseases including familial Mediterranean fever (FMF). The aim of this study was to determine the frequency of FD in patients with mild and severe FMF and to prevent misdiagnosis by increasing clinicians’ awareness.

Methods

Based on Tel-Hashomer criteria, the study included a total of 91 FMF patients. Patients were divided into two groups according to the number of recurrent clinical episodes or failure to respond to maximum therapy: those with mild and severe forms of the disease. GLA gene mutations and α-GLA enzyme activity were assessed. Records of MEFV mutations, therapies and demographic characteristics were kept.

Results

FD testing was performed on a cohort of 91 FMF patients, 54.9% had mild FMF, 45.1% had severe FMF, and only one patient in the mild FMF subgroup tested positive for FD. The patient was a 39-year-old woman with a history of recurrent abdominal pain, distal limb pain and fever. She had low GLA enzyme activity and a heterozygous GLA gene mutation.

Conclusions

Our findings suggest that FD should be considered in the differential diagnosis of FMF, especially in individuals with unusual symptoms.
目的α-半乳糖苷酶 A(GLA)基因突变导致法布里病(FD),这是一种罕见的代谢性疾病。法布里病患者的临床表现多种多样,可能与包括家族性地中海热(FMF)在内的全身性疾病重叠。本研究旨在确定 FD 在轻度和重度 FMF 患者中的发病率,并通过提高临床医生的认识来防止误诊。方法根据 Tel-Hashomer 标准,本研究共纳入 91 名 FMF 患者。根据临床反复发作的次数或对最大治疗无效的情况,将患者分为两组:轻度和重度FMF患者。对 GLA 基因突变和 α-GLA 酶活性进行了评估。对91名FMF患者进行了FD检测,其中54.9%为轻度FMF,45.1%为重度FMF,轻度FMF亚组中仅有一名患者的FD检测呈阳性。这名患者是一名 39 岁的女性,有反复腹痛、肢体远端疼痛和发热的病史。结论:我们的研究结果表明,在鉴别诊断 FMF 时应考虑 FD,尤其是症状异常的患者。
{"title":"Fabry disease in familial Mediterranean fever according to the severity of the disease","authors":"Sadettin Uslu ,&nbsp;Gökhan Kabadayi ,&nbsp;Pelin Teke Kısa ,&nbsp;Tuba Yüce Inel ,&nbsp;Zümrüt Arslan ,&nbsp;Nur Arslan ,&nbsp;Servet Akar ,&nbsp;Fatos Onen ,&nbsp;Ismail Sari","doi":"10.1016/j.reuma.2024.09.002","DOIUrl":"10.1016/j.reuma.2024.09.002","url":null,"abstract":"<div><h3>Objectives</h3><div>Mutations in the α-galactosidase A (GLA) gene result in Fabry disease (FD), a rare metabolic condition. FD patients present with heterogeneous clinical manifestations, which may overlap with systemic diseases including familial Mediterranean fever (FMF). The aim of this study was to determine the frequency of FD in patients with mild and severe FMF and to prevent misdiagnosis by increasing clinicians’ awareness.</div></div><div><h3>Methods</h3><div>Based on Tel-Hashomer criteria, the study included a total of 91 FMF patients. Patients were divided into two groups according to the number of recurrent clinical episodes or failure to respond to maximum therapy: those with mild and severe forms of the disease. GLA gene mutations and α-GLA enzyme activity were assessed. Records of MEFV mutations, therapies and demographic characteristics were kept.</div></div><div><h3>Results</h3><div>FD testing was performed on a cohort of 91 FMF patients, 54.9% had mild FMF, 45.1% had severe FMF, and only one patient in the mild FMF subgroup tested positive for FD. The patient was a 39-year-old woman with a history of recurrent abdominal pain, distal limb pain and fever. She had low GLA enzyme activity and a heterozygous GLA gene mutation.</div></div><div><h3>Conclusions</h3><div>Our findings suggest that FD should be considered in the differential diagnosis of FMF, especially in individuals with unusual symptoms.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 9","pages":"Pages 484-489"},"PeriodicalIF":1.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142578919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Guías de Práctica Clínica para el tratamiento del lupus eritematoso sistémico del Colegio Mexicano de Reumatología. Actualización 2024 墨西哥风湿病学会系统性红斑狼疮治疗临床实践指南。2024 年更新
IF 1.2 Q4 RHEUMATOLOGY Pub Date : 2024-11-01 DOI: 10.1016/j.reuma.2024.07.004
Lilia Andrade-Ortega , Daniel Xibillé-Friedmann , Dionicio A. Galarza-Delgado , Miguel Ángel Saavedra , José Alvarez-Nemegyei , Mary-Carmen Amigo-Castañeda , Hilda Fragoso-Loyo , María Vanessa Gordillo-Huerta , Fedra Irazoque-Palazuelos , Luis Javier Jara-Quezada† , Javier Merayo-Chalico , Margarita Portela-Hernández , Sandra Sicsik-Ayala , Carlos Abud-Mendoza , Deshire Alpizar-Rodriguez , José Luis Amaya-Estrada , Yaneth R. Barragán-Navarro , Sandra M. Carrillo-Vázquez , Zully Castro-Colín , Luis Javier Cruz-Álvarez , Leonor A. Barile-Fabris
Herein we present the update for the Mexican Guidelines for the Treatment of Systemic Lupus Erythematosus. It involves the participation of several experts along the country, following the GRADE system.
We included aspects regarding vaccines, pregnancy and cardiovascular risk which were not presented in the previous guidelines in 2017.
我们在此介绍《墨西哥系统性红斑狼疮治疗指南》的更新版。我们纳入了疫苗、妊娠和心血管风险等方面的内容,这些内容在 2017 年的前一份指南中并未介绍。
{"title":"Guías de Práctica Clínica para el tratamiento del lupus eritematoso sistémico del Colegio Mexicano de Reumatología. Actualización 2024","authors":"Lilia Andrade-Ortega ,&nbsp;Daniel Xibillé-Friedmann ,&nbsp;Dionicio A. Galarza-Delgado ,&nbsp;Miguel Ángel Saavedra ,&nbsp;José Alvarez-Nemegyei ,&nbsp;Mary-Carmen Amigo-Castañeda ,&nbsp;Hilda Fragoso-Loyo ,&nbsp;María Vanessa Gordillo-Huerta ,&nbsp;Fedra Irazoque-Palazuelos ,&nbsp;Luis Javier Jara-Quezada† ,&nbsp;Javier Merayo-Chalico ,&nbsp;Margarita Portela-Hernández ,&nbsp;Sandra Sicsik-Ayala ,&nbsp;Carlos Abud-Mendoza ,&nbsp;Deshire Alpizar-Rodriguez ,&nbsp;José Luis Amaya-Estrada ,&nbsp;Yaneth R. Barragán-Navarro ,&nbsp;Sandra M. Carrillo-Vázquez ,&nbsp;Zully Castro-Colín ,&nbsp;Luis Javier Cruz-Álvarez ,&nbsp;Leonor A. Barile-Fabris","doi":"10.1016/j.reuma.2024.07.004","DOIUrl":"10.1016/j.reuma.2024.07.004","url":null,"abstract":"<div><div>Herein we present the update for the Mexican Guidelines for the Treatment of Systemic Lupus Erythematosus. It involves the participation of several experts along the country, following the GRADE system.</div><div>We included aspects regarding vaccines, pregnancy and cardiovascular risk which were not presented in the previous guidelines in 2017.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 9","pages":"Pages 490-510"},"PeriodicalIF":1.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142578920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Miositis por cuerpos de inclusión: informe de un caso de diagnóstico tardío 包涵体肌炎:一份晚期诊断病例报告
IF 1.2 Q4 RHEUMATOLOGY Pub Date : 2024-11-01 DOI: 10.1016/j.reuma.2024.07.003
Deysi Andrea Hernández-Rivero , Lisette Bazán-Rodríguez , María del Pilar Cruz-Domínguez , Gabriela Medina , Ana Lilia Peralta Amaro , Olga Vera-Lastra
Inclusion body myositis is a idiopathic inflammatory myopathy characterized by muscle weakness and dysphagia, with muscle biopsy showing inflammation and rimmed vacuoles. We present the case of a patient who was diagnosed with polymyositis but due to lack of response to treatment, a new biopsy revealed inclusion body myositis.
包涵体肌炎是一种特发性炎症性肌病,以肌无力和吞咽困难为特征,肌肉活检显示炎症和边缘空泡。我们介绍了一例患者的病例,该患者曾被诊断为多发性肌炎,但由于对治疗缺乏反应,新的活组织检查发现了包涵体肌炎。
{"title":"Miositis por cuerpos de inclusión: informe de un caso de diagnóstico tardío","authors":"Deysi Andrea Hernández-Rivero ,&nbsp;Lisette Bazán-Rodríguez ,&nbsp;María del Pilar Cruz-Domínguez ,&nbsp;Gabriela Medina ,&nbsp;Ana Lilia Peralta Amaro ,&nbsp;Olga Vera-Lastra","doi":"10.1016/j.reuma.2024.07.003","DOIUrl":"10.1016/j.reuma.2024.07.003","url":null,"abstract":"<div><div>Inclusion body myositis is a idiopathic inflammatory myopathy characterized by muscle weakness and dysphagia, with muscle biopsy showing inflammation and rimmed vacuoles. We present the case of a patient who was diagnosed with polymyositis but due to lack of response to treatment, a new biopsy revealed inclusion body myositis.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 9","pages":"Pages 511-512"},"PeriodicalIF":1.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142578921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalencia del entesofito occipital en enfermedades reumáticas inflamatorias y no inflamatorias 炎症性和非炎症性风湿病的枕骨骨结核发病率
IF 1.2 Q4 RHEUMATOLOGY Pub Date : 2024-11-01 DOI: 10.1016/j.reuma.2024.06.004
Natalia de la Torre Rubio, Jose Campos Esteban, José Luis Andréu Sánchez, Jesús Sanz Sanz
{"title":"Prevalencia del entesofito occipital en enfermedades reumáticas inflamatorias y no inflamatorias","authors":"Natalia de la Torre Rubio,&nbsp;Jose Campos Esteban,&nbsp;José Luis Andréu Sánchez,&nbsp;Jesús Sanz Sanz","doi":"10.1016/j.reuma.2024.06.004","DOIUrl":"10.1016/j.reuma.2024.06.004","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 9","pages":"Pages 513-514"},"PeriodicalIF":1.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142578922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
La fibromialgia con factor reumatoide elevado se asocia a mala respuesta terapéutica pero no con progresión a artritis reumatoide. Estudio de cohortes prospectivo 类风湿因子升高的纤维肌痛与治疗反应不佳有关,但与发展为类风湿关节炎无关。前瞻性队列研究
IF 1.2 Q4 RHEUMATOLOGY Pub Date : 2024-11-01 DOI: 10.1016/j.reuma.2024.06.005
Freddy Liñán Ponce, Juan Leiva Goicochea, David Sevilla Rodríguez, Elmer Hidalgo Bravo, Ginna Obregón Atanacio, Inés Loyola Macalapú, Paola Jáuregui Rojas, Jackeline Yampufe Canani

Objective

Evaluate response to treatment and progression to rheumatoid arthritis (RA) in patients with fibromyalgia (FM) associated with elevated rheumatoid factor (RF).

Material and methods

Prospective cohort study. The sample consisted of 124 patients with FM: 62 with high RF (> 20 U/ml) and 62 with negative RF (0-20 U/ml). All patients were evaluated using FM treatment improvement score (FIQR) and progression to RA according to EULAR/ACR 2010 criteria at 6 and 12 months. Pearson's χ2 test for homogeneity was used to relate variables of improvement to FM treatment and progression to RA.

Results

The response to treatment was lower in the high RF group (24 and 20 patients improved at 6 and 12 months, respectively, compared to 45 and 38 patients in the negative RF group), with a significant difference. Progression to rheumatoid arthritis was similar in both groups (5 in the high RF group and 4 in the negative RF group), with a non-significant relationship.

Conclusions

FM with elevated RF is associated with a poor therapeutic response but not with progression to RA.
目的评估类风湿因子(RF)升高的纤维肌痛(FM)患者对治疗的反应以及发展为类风湿关节炎(RA)的情况。样本包括 124 名 FM 患者:62 名 RF 偏高(> 20 U/ml),62 名 RF 偏低(0-20 U/ml)。根据 EULAR/ACR 2010 标准,使用 FM 治疗改善评分(FIQR)对所有患者进行评估,并在 6 个月和 12 个月后评估其是否进展为 RA。结果高RF组的治疗反应较低(6个月和12个月时分别有24名和20名患者好转,而阴性RF组分别有45名和38名患者好转),差异显著。两组患者进展为类风湿性关节炎的情况相似(高RF组5例,阴性RF组4例),但关系不显著。
{"title":"La fibromialgia con factor reumatoide elevado se asocia a mala respuesta terapéutica pero no con progresión a artritis reumatoide. Estudio de cohortes prospectivo","authors":"Freddy Liñán Ponce,&nbsp;Juan Leiva Goicochea,&nbsp;David Sevilla Rodríguez,&nbsp;Elmer Hidalgo Bravo,&nbsp;Ginna Obregón Atanacio,&nbsp;Inés Loyola Macalapú,&nbsp;Paola Jáuregui Rojas,&nbsp;Jackeline Yampufe Canani","doi":"10.1016/j.reuma.2024.06.005","DOIUrl":"10.1016/j.reuma.2024.06.005","url":null,"abstract":"<div><h3>Objective</h3><div>Evaluate response to treatment and progression to rheumatoid arthritis (RA) in patients with fibromyalgia (FM) associated with elevated rheumatoid factor (RF).</div></div><div><h3>Material and methods</h3><div>Prospective cohort study. The sample consisted of 124 patients with FM: 62 with high RF (&gt;<!--> <!-->20<!--> <!-->U/ml) and 62 with negative RF (0-20<!--> <!-->U/ml). All patients were evaluated using FM treatment improvement score (FIQR) and progression to RA according to EULAR/ACR 2010 criteria at 6 and 12 months. Pearson's χ<sup>2</sup> test for homogeneity was used to relate variables of improvement to FM treatment and progression to RA.</div></div><div><h3>Results</h3><div>The response to treatment was lower in the high RF group (24 and 20 patients improved at 6 and 12<!--> <!-->months, respectively, compared to 45 and 38 patients in the negative RF group), with a significant difference. Progression to rheumatoid arthritis was similar in both groups (5 in the high RF group and 4 in the negative RF group), with a non-significant relationship.</div></div><div><h3>Conclusions</h3><div>FM with elevated RF is associated with a poor therapeutic response but not with progression to RA.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 9","pages":"Pages 459-462"},"PeriodicalIF":1.2,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142578915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multicentric reticulohistiocytosis: A 20-year diagnosis beneath the surface 多中心网状组织细胞增生症:表面下的 20 年诊断
IF 1.2 Q4 RHEUMATOLOGY Pub Date : 2024-10-01 DOI: 10.1016/j.reuma.2024.07.005
David Fernández-Fernández , Ivonne Lourdes Mamani-Velarde , Maritza Tatiana Segarra-Ortega , José María Pego-Reigosa
{"title":"Multicentric reticulohistiocytosis: A 20-year diagnosis beneath the surface","authors":"David Fernández-Fernández ,&nbsp;Ivonne Lourdes Mamani-Velarde ,&nbsp;Maritza Tatiana Segarra-Ortega ,&nbsp;José María Pego-Reigosa","doi":"10.1016/j.reuma.2024.07.005","DOIUrl":"10.1016/j.reuma.2024.07.005","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 8","pages":"Pages 456-457"},"PeriodicalIF":1.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142357986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Frailty assessment in patients with Behçet's syndrome: A cross-sectional monocentric study 贝赫切特综合征患者的虚弱评估:横断面单中心研究
IF 1.2 Q4 RHEUMATOLOGY Pub Date : 2024-10-01 DOI: 10.1016/j.reuma.2024.04.004
Hakan Apaydin , Serdar Can Güven , Rezan Koçak Ulucaköy , Hakan Babaoğlu , Esra Kayacan Erdoğan , Kevser Orhan , Berkan Armağan

Aims

Evidence evaluating the association between pre-frailty and frailty, and risk of adverse health outcomes in patients with Behçet's syndrome (BS) is limited in the literature. The aim of this study was to characterize the prevalence of frailty and associated factors in a single-centre cohort of patients with BS.

Methods

Based on the International Study Group's criteria, this was a monocentric cross-sectional study of BS patients. The Fried frailty criteria were used to define frailty. The Turkish version of the Behçet's Disease Current Activity Form was used to measure the disease activity of BS. Damage index was assessed with the Behçet's Syndrome Overall Damage Index.

Results

Forty-four patients were enrolled. According to Fried frailty criteria, patients were classified as 13.6% frail, 59% pre-frail, and 27.2% robust, respectively. Compared to pre-frail and robust patients, frail patients had higher levels of inflammatory markers at the time of diagnosis. CRP levels at time of diagnosis and at the last visit were higher in the frail group than in the pre-frail and robust groups (p = 0.039 and p = 0.023, respectively). When active drugs for BS were evaluated, systemic glucocorticoid (50%, p = 0.030) and cyclophosphamide (33.3%, p = 0.006) treatments were higher in the frail group.

Conclusions

Frailty and pre-frailty are commonly detected even in younger patients with BS. Inflammation can be described as potential determinants of frailty status.
目的文献中评估贝赫切特综合征(BS)患者虚弱前和虚弱与不良健康后果风险之间关系的证据有限。本研究的目的是在一个单一中心的贝赫切特综合征患者队列中描述虚弱的发生率和相关因素。方法根据国际研究小组的标准,这是一项针对贝赫切特综合征患者的单中心横断面研究。弗里德虚弱标准用于定义虚弱。采用土耳其版的贝赫切特病活动度表来测量 BS 的疾病活动度。贝赫切特综合征总体损害指数用于评估损害指数。根据弗里德虚弱标准,患者中虚弱者占 13.6%,前期虚弱者占 59%,健壮者占 27.2%。与体弱前期和体格健壮的患者相比,体弱患者在确诊时的炎症标志物水平较高。体弱组在诊断时和最后一次就诊时的 CRP 水平均高于体弱前组和健壮组(分别为 p = 0.039 和 p = 0.023)。在评估治疗 BS 的活性药物时,体弱组使用全身糖皮质激素(50%,p = 0.030)和环磷酰胺(33.3%,p = 0.006)治疗的比例更高。炎症可被视为虚弱状态的潜在决定因素。
{"title":"Frailty assessment in patients with Behçet's syndrome: A cross-sectional monocentric study","authors":"Hakan Apaydin ,&nbsp;Serdar Can Güven ,&nbsp;Rezan Koçak Ulucaköy ,&nbsp;Hakan Babaoğlu ,&nbsp;Esra Kayacan Erdoğan ,&nbsp;Kevser Orhan ,&nbsp;Berkan Armağan","doi":"10.1016/j.reuma.2024.04.004","DOIUrl":"10.1016/j.reuma.2024.04.004","url":null,"abstract":"<div><h3>Aims</h3><div>Evidence evaluating the association between pre-frailty and frailty, and risk of adverse health outcomes in patients with Behçet's syndrome (BS) is limited in the literature. The aim of this study was to characterize the prevalence of frailty and associated factors in a single-centre cohort of patients with BS.</div></div><div><h3>Methods</h3><div>Based on the International Study Group's criteria, this was a monocentric cross-sectional study of BS patients. The Fried frailty criteria were used to define frailty. The Turkish version of the Behçet's Disease Current Activity Form was used to measure the disease activity of BS. Damage index was assessed with the Behçet's Syndrome Overall Damage Index.</div></div><div><h3>Results</h3><div>Forty-four patients were enrolled. According to Fried frailty criteria, patients were classified as 13.6% frail, 59% pre-frail, and 27.2% robust, respectively. Compared to pre-frail and robust patients, frail patients had higher levels of inflammatory markers at the time of diagnosis. CRP levels at time of diagnosis and at the last visit were higher in the frail group than in the pre-frail and robust groups (<em>p</em> <!-->=<!--> <!-->0.039 and <em>p</em> <!-->=<!--> <!-->0.023, respectively). When active drugs for BS were evaluated, systemic glucocorticoid (50%, <em>p</em> <!-->=<!--> <!-->0.030) and cyclophosphamide (33.3%, <em>p</em> <!-->=<!--> <!-->0.006) treatments were higher in the frail group.</div></div><div><h3>Conclusions</h3><div>Frailty and pre-frailty are commonly detected even in younger patients with BS. Inflammation can be described as potential determinants of frailty status.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 8","pages":"Pages 409-415"},"PeriodicalIF":1.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142357999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Actualización del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas y sintéticas dirigidas en la artritis reumatoide 西班牙风湿病学会关于在类风湿性关节炎中使用生物和合成靶向疗法的共识文件更新版
IF 1.2 Q4 RHEUMATOLOGY Pub Date : 2024-10-01 DOI: 10.1016/j.reuma.2024.05.007
José María Álvaro-Gracia Álvaro , Petra Díaz del Campo Fontecha , José Luis Andréu Sánchez , Alejandro Balsa Criado , Rafael Cáliz Cáliz , Isabel Castrejón Fernández , Hèctor Corominas , José A. Gómez Puerta , Sara Manrique Arija , Natalia Mena Vázquez , Ana Ortiz García , Chamaida Plasencia Rodríguez , Lucía Silva Fernández , Jesús Tornero Molina

Objective

To update the consensus document of the Spanish Society of Rheumatology (SER) regarding the use of targeted biological and synthetic therapies in rheumatoid arthritis (RA) with the aim of assisting clinicians in their therapeutic decisions.

Methods

A panel of 13 experts was assembled through an open call by SER. We employed a mixed adaptation-elaboration-update methodology starting from the 2015 Consensus Document of the Spanish Society of Rheumatology on the use of biological therapies in RA. Starting with systematic reviews (SR) of recommendations from EULAR 2019, American College of Rheumatology 2021, and GUIPCAR 2017, we updated the search strategies for the PICO questions of GUIPCAR. An additional SR was conducted on demyelinating disease in relation to targeted biological and synthetic therapies. Following the analysis of evidence by different panelists, consensus on the wording and level of agreement for each recommendation was reached in a face-to-face meeting.

Results

The panel established 5 general principles and 15 recommendations on the management of RA. These encompassed crucial aspects such as the importance of early treatment, therapeutic goals in RA, monitoring frequency, the use of glucocorticoids, the application of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biological DMARDs (bDMARDs), and targeted synthetic DMARDs. Additionally, recommendations on dose reduction of these drugs in stable patients were included. This update also features recommendations on the use of bDMARDs and Janus Kinase inhibitors in some specific clinical situations, such as patients with lung disease, a history of cancer, heart failure, or demyelinating disease.

Conclusions

This update provides recommendations on key aspects in the management of RA using targeted biological and synthetic therapies.
目的更新西班牙风湿病学会(SER)关于类风湿性关节炎(RA)使用靶向生物和合成疗法的共识文件,以协助临床医生做出治疗决策。方法通过西班牙风湿病学会的公开征集,组建了一个由 13 位专家组成的小组。我们从 2015 年西班牙风湿病学会关于在 RA 中使用生物疗法的共识文件开始,采用了改编-阐述-更新的混合方法。从 EULAR 2019、American College of Rheumatology 2021 和 GUIPCAR 2017 建议的系统回顾(SR)开始,我们更新了 GUIPCAR PICO 问题的检索策略。我们还就脱髓鞘疾病与靶向生物和合成疗法的关系进行了额外的SR研究。不同的专家组成员对证据进行分析后,在一次面对面的会议上就每项建议的措辞和一致程度达成了共识。这些建议包括早期治疗的重要性、RA 的治疗目标、监测频率、糖皮质激素的使用、常规合成改善病情抗风湿药(csDMARDs)、生物 DMARDs(bDMARDs)和靶向合成 DMARDs 的应用等重要方面。此外,还包括对病情稳定的患者减少这些药物剂量的建议。本更新版还就在某些特殊临床情况下使用生物DMARDs和Janus激酶抑制剂提出了建议,如患有肺部疾病、癌症病史、心力衰竭或脱髓鞘疾病的患者。结论本更新版就使用靶向生物和合成疗法治疗RA的关键方面提出了建议。
{"title":"Actualización del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas y sintéticas dirigidas en la artritis reumatoide","authors":"José María Álvaro-Gracia Álvaro ,&nbsp;Petra Díaz del Campo Fontecha ,&nbsp;José Luis Andréu Sánchez ,&nbsp;Alejandro Balsa Criado ,&nbsp;Rafael Cáliz Cáliz ,&nbsp;Isabel Castrejón Fernández ,&nbsp;Hèctor Corominas ,&nbsp;José A. Gómez Puerta ,&nbsp;Sara Manrique Arija ,&nbsp;Natalia Mena Vázquez ,&nbsp;Ana Ortiz García ,&nbsp;Chamaida Plasencia Rodríguez ,&nbsp;Lucía Silva Fernández ,&nbsp;Jesús Tornero Molina","doi":"10.1016/j.reuma.2024.05.007","DOIUrl":"10.1016/j.reuma.2024.05.007","url":null,"abstract":"<div><h3>Objective</h3><div>To update the consensus document of the Spanish Society of Rheumatology (SER) regarding the use of targeted biological and synthetic therapies in rheumatoid arthritis (RA) with the aim of assisting clinicians in their therapeutic decisions.</div></div><div><h3>Methods</h3><div>A panel of 13 experts was assembled through an open call by SER. We employed a mixed adaptation-elaboration-update methodology starting from the 2015 Consensus Document of the Spanish Society of Rheumatology on the use of biological therapies in RA. Starting with systematic reviews (SR) of recommendations from EULAR 2019, American College of Rheumatology 2021, and GUIPCAR 2017, we updated the search strategies for the PICO questions of GUIPCAR. An additional SR was conducted on demyelinating disease in relation to targeted biological and synthetic therapies. Following the analysis of evidence by different panelists, consensus on the wording and level of agreement for each recommendation was reached in a face-to-face meeting.</div></div><div><h3>Results</h3><div>The panel established 5 general principles and 15 recommendations on the management of RA. These encompassed crucial aspects such as the importance of early treatment, therapeutic goals in RA, monitoring frequency, the use of glucocorticoids, the application of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biological DMARDs (bDMARDs), and targeted synthetic DMARDs. Additionally, recommendations on dose reduction of these drugs in stable patients were included. This update also features recommendations on the use of bDMARDs and Janus Kinase inhibitors in some specific clinical situations, such as patients with lung disease, a history of cancer, heart failure, or demyelinating disease.</div></div><div><h3>Conclusions</h3><div>This update provides recommendations on key aspects in the management of RA using targeted biological and synthetic therapies.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 8","pages":"Pages 423-439"},"PeriodicalIF":1.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141688982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Controversia en el uso y en la financiación de SYSADOA para la osteoartritis en España: un análisis del debate científico-social en los medios de comunicación 西班牙骨关节炎使用和资助 SYSADOA 的争议:媒体社会科学辩论分析
IF 1.2 Q4 RHEUMATOLOGY Pub Date : 2024-10-01 DOI: 10.1016/j.reuma.2024.05.002
Pedro Alfonso Domínguez Vera , Luis Carrasco Páez

Background and objective

The use of SYmptomatic Slow-Acting Drugs for Osteoarthritis (SYSADOA) in the treatment of osteoarthritis (OA) has been a topic of debate in the scientific community and public entities regarding their public financing in Spain. The objective of this study was to describe and analyze the main positions of media outlets, public entities, regarding the use and financing of SYSADOA in Spain.

Methods

A qualitative and quantitative analysis of the content regarding the use and financing of SYSADOA was conducted in general media outlets (El País, El Mundo, La Vanguardia, ABC, and 20minutos), public statements, and Twitter® publications.

Results

A total of 15 articles in general media outlets, 872 tweets, and 7 public entity statements were identified. Mostly, media outlets (91%) and social media platforms (78%) exhibited a favorable trend towards funding.

Discussion and conclusions

The use of SYSADOA in OA patients continues to be controversial in the scientific community. However, there is consensus among patient associations in favor of public funding and use as a treatment for OA patients.
背景和目的在西班牙,骨关节炎慢作用药物 SYSADOA(SYmptomatic Slow-Acting Drugs for Osteoarthritis)在治疗骨关节炎(OA)方面的应用一直是科学界和公共实体就其公共融资问题争论不休的话题。本研究旨在描述和分析媒体、公共实体对西班牙使用和资助 SYSADOA 的主要立场。研究方法对一般媒体(El País、El Mundo、La Vanguardia、ABC 和 20minutos)、公共声明和 Twitter® 出版物中有关 SYSADOA 使用和资助的内容进行了定性和定量分析。结果共发现 15 篇一般媒体文章、872 条微博和 7 份公共实体声明。大多数媒体(91%)和社交媒体平台(78%)对资助表现出了积极的趋势。讨论与结论在 OA 患者中使用 SYSADOA 在科学界仍存在争议。然而,患者协会已达成共识,赞成公共资助并将其用作治疗 OA 患者的方法。
{"title":"Controversia en el uso y en la financiación de SYSADOA para la osteoartritis en España: un análisis del debate científico-social en los medios de comunicación","authors":"Pedro Alfonso Domínguez Vera ,&nbsp;Luis Carrasco Páez","doi":"10.1016/j.reuma.2024.05.002","DOIUrl":"10.1016/j.reuma.2024.05.002","url":null,"abstract":"<div><h3>Background and objective</h3><div>The use of SYmptomatic Slow-Acting Drugs for Osteoarthritis (SYSADOA) in the treatment of osteoarthritis (OA) has been a topic of debate in the scientific community and public entities regarding their public financing in Spain. The objective of this study was to describe and analyze the main positions of media outlets, public entities, regarding the use and financing of SYSADOA in Spain.</div></div><div><h3>Methods</h3><div>A qualitative and quantitative analysis of the content regarding the use and financing of SYSADOA was conducted in general media outlets (<em>El País</em>, <em>El Mundo, La Vanguardia, ABC,</em> and <em>20minutos</em>), public statements, and Twitter® publications.</div></div><div><h3>Results</h3><div>A total of 15 articles in general media outlets, 872 tweets, and 7 public entity statements were identified. Mostly, media outlets (91%) and social media platforms (78%) exhibited a favorable trend towards funding.</div></div><div><h3>Discussion and conclusions</h3><div>The use of SYSADOA in OA patients continues to be controversial in the scientific community. However, there is consensus among patient associations in favor of public funding and use as a treatment for OA patients.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 8","pages":"Pages 416-422"},"PeriodicalIF":1.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141695971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of psychological interventions to reduce anxiety and depression in patients with lupus. A systematic review and meta-analysis 减少狼疮患者焦虑和抑郁的心理干预措施的疗效。系统回顾与荟萃分析
IF 1.2 Q4 RHEUMATOLOGY Pub Date : 2024-10-01 DOI: 10.1016/j.reuma.2024.06.006
Jose Luis Vicente-Escudero
The presence of anxiety and depression symptoms in patients with lupus is common, and some research reports that psychological interventions can reduce them, therefore we conducted a systematic review and meta-analysis of the efficacy of psychological interventions in adults with systemic lupus erythematosus. Randomized and non-randomized clinical trials with adult population diagnosed with lupus, treated with psychological intervention, and compared with similar groups were selected. Several databases were searched in July 2023. Fourteen studies were included in the meta-analysis, with moderate effect sizes for anxiety and depression in group intervention modalities. Factors such as percentage of sample with lupus, gender, medication, and interventions with relaxation components influenced the results. Group psychological intervention programs are effective in reducing symptoms in patients with lupus, although further research on treatment modulating variables is needed.
红斑狼疮患者普遍存在焦虑和抑郁症状,一些研究报告称心理干预可减轻这些症状,因此我们对心理干预对成年系统性红斑狼疮患者的疗效进行了系统回顾和荟萃分析。我们选择了以确诊为红斑狼疮、接受心理干预治疗并与同类人群进行比较的成人为对象的随机和非随机临床试验。2023 年 7 月,对多个数据库进行了检索。14项研究被纳入了荟萃分析,在团体干预模式中,焦虑和抑郁的效应大小适中。红斑狼疮患者的比例、性别、药物治疗以及含有放松成分的干预措施等因素都会影响研究结果。团体心理干预计划能有效减轻狼疮患者的症状,但仍需进一步研究治疗调节变量。
{"title":"Efficacy of psychological interventions to reduce anxiety and depression in patients with lupus. A systematic review and meta-analysis","authors":"Jose Luis Vicente-Escudero","doi":"10.1016/j.reuma.2024.06.006","DOIUrl":"10.1016/j.reuma.2024.06.006","url":null,"abstract":"<div><div>The presence of anxiety and depression symptoms in patients with lupus is common, and some research reports that psychological interventions can reduce them, therefore we conducted a systematic review and meta-analysis of the efficacy of psychological interventions in adults with systemic lupus erythematosus. Randomized and non-randomized clinical trials with adult population diagnosed with lupus, treated with psychological intervention, and compared with similar groups were selected. Several databases were searched in July 2023. Fourteen studies were included in the meta-analysis, with moderate effect sizes for anxiety and depression in group intervention modalities. Factors such as percentage of sample with lupus, gender, medication, and interventions with relaxation components influenced the results. Group psychological intervention programs are effective in reducing symptoms in patients with lupus, although further research on treatment modulating variables is needed.</div></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 8","pages":"Pages 440-451"},"PeriodicalIF":1.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142357984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Reumatologia Clinica
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1